APLS

Apellis Pharmaceuticals, Inc. (APLS) | Rumor.io

Apellis Pharmaceuticals

APLS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)88%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about APLS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

May 21

Copper demand is projected to grow from 28M to 42M tonnes by 2040, providing a potential tailwind for NovaRed Mining Inc. (CSE: NRED).
NovaRed's copper exposure and district-scale land in BC make it well-positioned for the copper-driven infrastructure boom, with the company's AI mineral scoring and IP angle being underappreciated by the market.
NovaRed's copper supply is expected to fit the "new supply matters" trade, with the company's assets and potential for growth making it an attractive investment opportunity.

Generated by AI

Sentiment

Of the messages about APLS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	83.33% -2.87	83.76% +12.1
Bearish	0%	0% 0	16.67% +2.87	16.24% -12.1

Bullish· Apr 1

Apellis Pharmaceuticals, Inc. (APLS) has achieved a significant compliance milestone, leading to a 135.40% surge in its stock price.
The company's acquisition by Biogen for $5.6 billion validates its pipeline and has been a major catalyst for its stock price growth.
The acquisition by Biogen has also led to a significant increase in institutional positioning, with smart money flow driving the stock's rally.

Bearish· Mar 31

$APLS has experienced a significant decline in price, dropping from $41.X to $17.09 in just 3 months.
The stock's short interest is high, indicating a potential bearish sentiment among investors.
$APLS has a history of being sold off after positive news, leading to a loss of investor faith and a subsequent decline in price.

Generated by AI

Topics

Of the messages about APLS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	17.1%
Announcements	100%	66.67%	50%	69.67%
Controversies	0%	0%	0%	0.57%
Earnings	0%	0%	37.5%	2.45%
Macro	0%	33.33%	12.5%	4.94%
Technical Analysis	0%	0%	0%	5.27%

Analysts· Oct 6

JPMorgan upgraded Apellis Pharmaceuticals to Overweight from Neutral with a price target of $81, up from $60.
Citigroup raised the firm's price target on Apellis Pharmaceuticals to $70 from $54 and keeps a Buy rating.
Apellis Pharmaceuticals has a 81% buy consensus among 21 analysts, with a strong demand for its SYFOVRE product and a permanent J-code effective as of October 1.

Announcements· Apr 1

Apellis Pharmaceuticals ($APLS) surges 135% after Biogen acquires the company for $5.6B, expanding Biogen's rare disease pipeline.
The acquisition price of $41 per share plus a contingent value right (CVR) worth up to $4 more per share is a significant catalyst for the stock.
Apellis' drugs Syfovre and Empaveli are expected to add around $689M to Biogen's revenue, with 15-20% growth potential through 2028.

Technical Analysis· Aug 1

The chart for APLS is showing a potential double bottom at $24.09 and $24.14, which could indicate a reversal in the stock's downward trend.
The stock's MACD is starting to curve upward, and with RSI so negative, it's ready to squeeze shorts, potentially leading to a major price increase.
The stock is currently trading at important long-term support levels, and if bulls fail to defend it, it could drop below $20, but there's also potential for a gradual reversal and a bounce to the high 20s.

Generated by AI

Community

Of the messages about APLS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	82.35%	50%	60.19%
Newcomers	0%	17.65%	50%	39.81%

Regulars· Mar 31

Biogen is acquiring Apellis Pharmaceuticals for $5.6 billion, with stockholders also receiving Contingent Value Rights (CVRs) for each Apellis share held.
The acquisition values the deal at $41 per share in cash, and Apellis will be a part of Biogen's kidney franchise.
Regulars who held onto Apellis for most of 2025 are congratulated on the profit, but some note they didn't make a penny from the buyout.

Newcomers· Apr 1

The newcomer is focusing on the significant price surge of $APLS, reaching +135.40% after Biogen's acquisition announcement.
The discussion highlights the merger documents and the potential for the spread to normalize soon, with some users expecting the stock to trade in the mid-40s.
The recent insider trading and critical compliance milestone are being seen as catalysts for the stock's upward trend, with some users noting the validation of the pipeline through the acquisition by Biogen.

Generated by AI

Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase […]

2mo agoYahoo Finance

Also Discussed

Investors talking about APLS also mention

#	Name	Attention
1	ISEE - IVERIC bio, Inc.	——
2	CNTA - Centessa Pharmaceuticals plc	——
3	SWTX - SpringWorks Therapeutics, Inc.	——
4	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
5	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
6	4D Molecular Therapeutics, Inc.FDMT	0%new
7	MRTX - Mirati Therapeutics, Inc.	——
8	Lineage Cell Therapeutics Inc.LCTX	0%-0.01
9	Rhythm Pharmaceuticals, Inc.RYTM	0%0
10	IDEAYA Biosciences Inc.IDYA	0%0